Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy with depigmented and polymerized Dermatophagoides pteronyssinus extract in allergic asthma
2006-000602-23Phase 3Withdrawn
- Sponsor
- LETI Pharma
- Start
- May 2007
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of depigoid dermatophagoides pteronyssinus in allergic asthma (2 arms), sponsored by LETI Pharma. Primary endpoint: Symptom plus medication score over one year of treatment. Planned start May 2007; status: withdrawn.
02
Drugs
depigoid dermatophagoides pteronyssinus
03
Conditions
allergic asthma
Beyond the preview
Go deeper on 2006-000602-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000602-23.